Company intelligence / Profile preview

QVQ

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

QVQ is a pioneer in camelid-derived single-domain antibody technology. The company offers contract research services covering the full spectrum from immunization to production/optimization of nanobodies. It also sells validated off-the-shelf VHHs for various biomedical applications. There are no clinical trial results as the company primarily provides reagents/tools rather than developing its own therapeutic pipeline

Therapeutic areas: OncologyInfectious DiseasesNeurologyOther
Modalities: Nanobody therapyAntibodyMonoclonal antibody fragmentHumanized single-chain antibody fragment (single-domain antibody, VHH, sdAb)
Industry: Non-Drug Biotech

Partnerships

SMEsLarge pharmaceutical companies

Beyond the preview

Go deeper on QVQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QVQ.

Explore the full profile